← Back to Search

Cases for Esophageal Neoplasms (FBE Trial)

N/A
Recruiting
Led By Amitabh Chak, MD
Research Sponsored by Case Western Reserve University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week
Awards & highlights
No Placebo-Only Group

Summary

This trial is focused on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA), and translating laboratory discoveries into clinical applications for effective detection, molecular risk stratification, and prevention of progression from BE to EAC.

Eligible Conditions
  • Esophageal Neoplasms
  • Barrett's Esophagus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assay of DNA and RNA markers
Secondary study objectives
Score of tolerability and acceptability

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: EGD ScreeningExperimental Treatment2 Interventions
Patients scheduled for clinically indicated EGD for GERD who meet ACG criteria for BE screening
Group II: ControlsExperimental Treatment2 Interventions
Patients scheduled for EGD who do not meet criteria for screening
Group III: Colon ScreeningExperimental Treatment2 Interventions
Patients scheduled for screening colonoscopy who have not had EGD and meet clinically indicated criteria for BE screening
Group IV: CasesExperimental Treatment2 Interventions
Patients with Barrett's esophagus undergoing surveillance or patients with esophageal adenocarcinoma and esophagogastric junctional adenocarcinoma undergoing EGD
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Endoscopy
2019
Completed Phase 3
~3480

Find a Location

Who is running the clinical trial?

University of North Carolina, Chapel HillOTHER
1,557 Previous Clinical Trials
4,297,052 Total Patients Enrolled
3 Trials studying Esophageal Neoplasms
1,129 Patients Enrolled for Esophageal Neoplasms
The Cleveland ClinicOTHER
1,053 Previous Clinical Trials
1,369,174 Total Patients Enrolled
2 Trials studying Esophageal Neoplasms
1,974 Patients Enrolled for Esophageal Neoplasms
University of PennsylvaniaOTHER
2,081 Previous Clinical Trials
42,722,820 Total Patients Enrolled
2 Trials studying Esophageal Neoplasms
248 Patients Enrolled for Esophageal Neoplasms
~322 spots leftby Jul 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top